Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sparsentan - Retrophin

Next Previous
Drug Profile

Sparsentan - Retrophin

Alternative Names: DARA; PS-433540; RE-021

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Retrophin
  • Class Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Focal segmental glomerulosclerosis; IgA nephropathy
  • Discontinued Hypertension

Most Recent Events

  • 14 Oct 2019 Retrophin announces intention to submit application for Conditional Marketing Authorization for IgA nephropathy
  • 14 Oct 2019 Retrophin announces intention to submit NDA to US FDA for IgA nephropathy
  • 27 Dec 2018 Phase-III clinical trials in IgA nephropathy in Estonia, Spain, Czech Republic (PO) (EudraCT2017-004605-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top